Auto-generated from public data. Not the firm's stated position.
Northislet appears to focus on growth-stage biotech investments, particularly in oncology and immunotherapy applications, with a disclosed check size starting at €3.0M. Recent portfolio activity suggests concentration in therapeutic innovation across personalized medicine and diagnostic platforms rather than the listed edtech sector.
Generated 14 Oct 2026 from disclosed sectors, stages, and portfolio companies. Firms can update this by emailing [email protected].
Focus and check size from the firm's website. Website reachable as of Sept 2026.
A fit check scores your pitch against their thesis, stage and ticket. An email draft uses their real deals and thesis, not a template.